Evidence map›Paper›PMID 31384535›Full record

ArticleActa pharmaceutica Sinica. B2019

Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.

Yayun Liu, Wei Xu, Ting Zhai, Jiaojiao You, Yong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Silybin A fromTheranostics · 2025
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yayun LiuHubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China.
Wei XuHubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China.
Ting ZhaiHubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China.
Jiaojiao YouHubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China.
Yong ChenHubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic steatohepatitis (NASH) is a chronic metabolic syndrome and the CFLAR-JNK pathway can reverse the process of NASH. Although silibinin is used for the treatment of NASH in clinical, its effect on CFLAR-JNK pathway in NASH remains unclear. This study aimed to investigate the effect of silibinin on CFLAR-JNK pathway in NASH models both

Indexed as

2-NBDG, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucoseAcox, acyl-coenzyme A oxidase XAkt, serine–threonine protein kinaseALT, alanine aminotransferaseAST, aspartate aminotransferaseCAT, catalaseCFLARCFLAR, caspase 8 and Fas-associated protein with death domain-like apoptosis regulatorCpt1α, carnitine palmitoyl transferase 1αCYP2E1, cytochrome P450 2E1CYP4A, cytochrome P450 4AFabp5, fatty acid-binding proteins 5Gpat, glycerol-3-phosphate acyltransferaseGSH-Px, glutathione peroxidaseHE, hematoxylin–eosinHO-1, heme oxygenase 1IR, insulin resistanceIRS1, insulin receptor substrate 1JNK, c-Jun N-terminal kinaseLipid accumulationMAPK, mitogen-activated protein kinaseMCD, methionine- and choline-deficientMCS, methionine- and choline-sufficientMDA, malondialdehydeMT, Masson–TrichromeMttp, microsomal triglyceride transfer proteinNAFLD, non-alcoholic fatty liver diseaseNASHNASH, nonalcoholic steatohepatitisNF-κB, nuclear factor κBNRF2, nuclear factor erythroid 2-related factor 2OA, oleic acidORO, oil red OOxidation stressPA, palmitic acidPI3K, phosphatidylinositol 3-hydroxy kinasepIRS1, phosphorylation of insulin receptor substrate 1pJNK, phosphorylation of c-Jun N-terminal kinasePnpla3, phospholipase domain containing 3Pparα, peroxisome proliferator activated receptor αScd-1, stearoyl-coenzyme A desaturase-1SD, Sprague–DawleySilibininSrebp-1c, sterol regulatory element binding protein-1CTC, total cholesterolTG, triglyceride

Identifiers

PMID31384535
PMCPMC6664044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.